Advanced Filters
noise

ovarian-cancer Clinical Trials

A listing of ovarian-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 561 clinical trials
J Jinming Yu

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are intolerant to standard therapies. XNW27011 is an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a transmembrane protein important …

18 years of age All Phase 1/2
E Elizabeth Heard

Early Phase Study of Kesonotide in Participants With Solid Tumours

This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic …

18 years of age All Phase 1/2
A Anne Grace, PhD

GYNecologic Cancer-Related COGnitive Impairment

The goal of this study is to test a home-based and patient-tailored cognitive training intervention among gynecologic cancer patients who have completed chemotherapy and who have experienced cancer-related cognitive impairment.

18 years of age Female Phase N/A
D David Shao Peng Tan

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.

21 - 99 years of age Female Phase 1
N Nancy Reynoso Noveron, M.D., M. Cs., Ph. D.

Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer

This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.

18 - 80 years of age Female Phase N/A
M Mónica Cebrián Coordinator Clinical Research Area

Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)

This clinical trial investigates the sentinel lymph node (SLN) technique as a less invasive alternative to conventional lymphadenectomy in patients with early-stage ovarian cancer. The primary objective is to evaluate the effectiveness, safety, and diagnostic accuracy of the SLN approach in detecting lymphatic metastases. By assessing its negative predictive value, …

18 years of age Female Phase 3

A Study of XMT-1660 in Participants With Solid Tumors

A Study of XMT-1660 in Solid Tumors

18 years of age All Phase 1

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration

Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).

18 years of age All Phase 1
C Cancer AnswerLine

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

18 years of age All Phase 1/2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

18 years of age All Phase 1

Simplify language using AI